To view or add a comment, sign in 2,461 followers
Key monitoring markers: IGF-1 levels (GH axis response) Fasting insulin and glucose (metabolic impact) hsCRP (inflammatory trajectory) Body composition (DEXA or InBody) Subjective quality: sleep depth, energy, recovery speed, cognitive clarity What the Evidence Supports and What It Does Not Intellectual honesty is part of good clinical practice
Weeks 48: When Most Patients Notice Meaningful Results By week 4, cumulative effects of semaglutide become apparent as your dose may be increased and your body fully adjusts to appetite suppression
These findings contribute to the growing body of literature suggesting that GLP-1based therapies may have applications beyond glycemic control, particularly in the context of hypogonadism related to obesity and insulin resistance
doi: 10.3390/nu13041136 181
doi: 10.1182/blood-2012-06-330845 43 LeeJJJacobsenEAMcGarryMPSchleimerRPLeeNA